Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole for GERD Symptom Assessment (COMPETITION)
NCT00336219Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2006
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of pantoprazole in gastroesophageal reflux disease (GERD), sponsored by Takeda. Primary endpoint: Symptom assessment as measured by ReQuest questionnaire and investigator at 28 days. Started Aug 2006; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00336219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336219.